Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2009-5-21
pubmed:abstractText
The human immunodeficiency virus type 1 (HIV-1) accessory protein Vif is encoded by an incompletely spliced mRNA resulting from splicing of the major splice donor in the HIV-1 genome, 5' splice site (5'ss) D1, to the first splice acceptor, 3'ss A1. We have shown previously that splicing of HIV-1 vif mRNA is tightly regulated by suboptimal 5'ss D2, which is 50 nucleotides downstream of 3'ss A1; a GGGG silencer motif proximal to 5'ss D2; and an SRp75-dependent exonic splicing enhancer (ESEVif). In agreement with the exon definition hypothesis, mutations within 5'ss D2 that are predicted to increase or decrease U1 snRNP binding affinity increase or decrease the usage of 3'ss A1 (D2-up and D2-down mutants, respectively). In this report, the importance of 5'ss D2 and ESEVif for avoiding restriction of HIV-1 by APOBEC3G (A3G) was determined by testing the infectivities of a panel of mutant viruses expressing different levels of Vif. The replication of D2-down and ESEVif mutants in permissive CEM-SS cells was not significantly different from that of wild-type HIV-1. Mutants that expressed Vif in 293T cells at levels greater than 10% of that of the wild type replicated similarly to the wild type in H9 cells, and Vif levels as low as 4% were affected only modestly in H9 cells. This is in contrast to Vif-deleted HIV-1, whose replication in H9 cells was completely inhibited. To test whether elevated levels of A3G inhibit replication of D2-down and ESEVif mutants relative to wild-type virus replication, a Tet-off Jurkat T-cell line that expressed approximately 15-fold-higher levels of A3G than control Tet-off cells was generated. Under these conditions, the fitness of all D2-down mutant viruses was reduced relative to that of wild-type HIV-1, and the extent of inhibition was correlated with the level of Vif expression. The replication of an ESEVif mutant was also inhibited only at higher levels of A3G. Thus, wild-type 5'ss D2 and ESEVif are required for production of sufficient Vif to allow efficient HIV-1 replication in cells expressing relatively high levels of A3G.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-11461998, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-12167863, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-12453430, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-12502829, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-12750511, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-12808465, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-12808466, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-12809610, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-14528300, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-14528301, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-14614829, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-15098018, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-15297452, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-15374000, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-15668174, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-15781449, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-16014920, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-16051840, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-16250885, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-16368153, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-16454710, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-16457729, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-17030806, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-17121840, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-17237417, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-18032510, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-18272582, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-18339206, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-3257102, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-8289374, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-8411338, http://linkedlifedata.com/resource/pubmed/commentcorrection/19357165-8523563
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1098-5514
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
83
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6067-78
pubmed:dateRevised
2010-9-27
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Regulation of Vif mRNA splicing by human immunodeficiency virus type 1 requires 5' splice site D2 and an exonic splicing enhancer to counteract cellular restriction factor APOBEC3G.
pubmed:affiliation
Department of Microbiology, University of Iowa, Iowa City, Iowa 52242, USA.
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural